Q1 saw sustained double-digit organic revenue growth, margin expansion across all P&L lines and healthy cash generation. Storytel exhibited flywheel dynamics, with solid net adds, a growing share of internal content consumption, higher engagement and retention, and improved customer acquisition efficiency. It continues to re-establish its industry-innovator perception with its popular AI VoiceSwitcher. While investors would prefer a clear main shareholder to trigger a re-rating, from an operatio...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 25 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transaction...
Stryve Foods, Inc. Announces Timing of Fiscal 2024 First Quarter Results PLANO, Texas, May 12, 2024 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today announces that it will release its fiscal 2024 first quarter results on Tuesday, May 14, 2024, after the market closes. In conjunction with the release, the Company has scheduled a conference call that will be hosted at 4:3...
We continue to believe the market is overlooking the sizeable Flexible Packaging step-up opportunity, with significant shareholder value potential from: 1) market share gains; 2) product simplification; and 3) footprint optimisation. With no estimate changes, we reiterate our BUY and EUR47 target price, and continue to find the NTM EV/EBIT of c12.5x (5-year average: c15.0x) attractive and a good entry point.
Tenaris to Commence a USD 300 million Third Tranche of its USD 1.2 Billion Share Buyback Program LUXEMBOURG, May 12, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) announced today that pursuant to its Share Buyback Program (the “Program”) announced on November 1, 2023, covering up to USD 1.2 billion to be executed in the open market with the intent to cancel the ordinary shares acquired through the Program, Tenaris has entered into a non-discretionary buyback agreement with a primary financial institution (the “Bank”). The Bank will make its tr...
Tenaris comenzará un Tercer Tramo de USD 300 millones de su Programa de Recompra de Acciones de USD 1,200 millones LUXEMBURGO, May 12, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE y Mexico: TS y EXM Italia: TEN) (“Tenaris”) anunció hoy que ha celebrado un acuerdo de recompra de acciones no discrecional con una institución financiera principal (el “Banco”) bajo su Programa de Recompra de Acciones (el “Programa”) anunciado el 1 de noviembre de 2023 por un monto de hasta USD1,200 millones a ser ejecutado en el mercado abierto con la intención de cancelar las acciones ordinarias compradas a tr...
iTeos meldet Finanzergebnisse für das erste Quartal 2024 und gibt aktuelle Geschäftsinformationen bekannt - Belrestotug + Dostarlimab übertraf die vordefinierten Wirksamkeitskriterien für klinisch relevante Aktivität, die in einer Zwischenbewertung der Phase 2 von GALAXIES Lung-201 beobachtet wurde - Klinisch bedeutsame Tumorreduktion wurde bei jeder Belrestotug + Dostarlimab-Dosis im Vergleich zur Monotherapie beobachtet - GSK wird bei der kommenden Investorenveranstaltung im Juni ein Update zum GALAXIES-Programm geben - RA Capital und Boxer Capital führen registrierte Direktemission in...
iTeos fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024 - Le doublet belrestotug + dostarlimab a dépassé les critères d’efficacité prédéfinis pour une activité cliniquement pertinente constatée lors d’une évaluation intérimaire de Phase 2 sur GALAXIES Lung-201 - Une réduction tumorale cliniquement significative a été observée à chaque administration de dose de belrestotug + dostarlimab par rapport à la monothérapie - GSK fournira une mise à jour du programme d’étude GALAXIES lors du prochain événement organisé à l’attention des investisseurs...
High Arctic Announces Reorganization to Create Two Energy Services Companies, Return of Capital to Shareholders, and Annual General and Special Meeting of Shareholders NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, May 11, 2024 (GLOBE NEWSWIRE) -- High Arctic Energy Services Inc. (TSX: HWO) ("High Arctic" or the "Corporation") is pleased to announce that its Board of Directors (“Board”) has unanimously approved the reorganization of Hi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.